


Attorney's Docket No. 5470-148CX



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Baldwin et al.

Serial No.: 08/959,160

Filed: 28 October 1997

For: **Use of NF- κ B Inhibition in
Combination Therapy for Cancer**

Group Art Unit: 1636

Examiner: T. McKelvey

Date: February 15, 2000

BOX CPA

Assistant Commissioner for Patents

Washington, DC 20231

PRELIMINARY REMARKS


Sir:

This Continued Prosecution Application (CPA) is being submitted in a good faith effort to advance prosecution and resolve the enablement rejection of record. Specifically, an opportunity to submit a Rule 132 declaration or conduct an interview prior to final action is respectfully requested.

Considerable evidence concerning the efficacy of the invention is available. A published paper is attached as Exhibit A, a paper in review is attached hereto as Exhibit B, and additional data is attached as Exhibit C. Applicants believe that either the instant claims should be allowable, or that claims can be formulated upon further discussion with the Examiner which should be allowable.

Accordingly, it is respectfully requested that the Examiner contact Applicants undersigned representative to discuss this case prior to any final action.

Respectfully submitted,



Kenneth D. Sibley
Registration No. 31,665

Correspondence Address

USPTO Customer No.: **20792**

Myers Bigel Sibley & Sajovec

P.O. Box 37428

Raleigh, North Carolina 27627

Telephone: 919-854-1400

Facsimile (919) 854-1401

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EL533388860US

Date of Deposit: February 15, 2000

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to: BOX CPA, Assistant Commissioner for Patents, Washington, DC 20231.



Kenneth D. Sibley

Date of Signature: February 15, 2000